Twist Bioscience, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brendan Smith from TD Cowen maintained a Buy rating on the stock and has a $36.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brendan Smith has given his Buy rating due to a combination of factors, primarily focusing on Twist Bioscience’s performance and future prospects. Despite some concerns about the SynBio segment’s near-term growth, the company has shown strong performance in its Next-Generation Sequencing (NGS) segment, which is expected to continue driving growth into 2026. This segment’s success highlights a clear path towards profitability, even as the SynBio outlook remains uncertain.
Another reason for the Buy rating is Twist’s resilience against broader market challenges, such as minimal exposure to China and growing revenues from academia, alongside negligible tariff impacts. Additionally, the company’s progress towards achieving adjusted EBITDA breakeven by the end of fiscal year 2026, bolstered by the spinout of their DNA data storage business, supports a positive long-term outlook. The revised price target of $36 reflects these growth assumptions and aligns more closely with peer trading multiples, reinforcing the Buy recommendation.